Repeatable acute rhabdomyolysis with multiple organ dysfunction because of interferon α and dacarbazine treatment in metastatic melanoma
A. Hauschild
Department of Dermatology, University of Kiel, Schittenhelmstr. 7, D-24105 Kiel, GermanyCorrespondence: Axel Hauschild, MD. E-mail: [email protected]
Search for more papers by this authorM. Möller
Department of Dermatology, University of Kiel, Schittenhelmstr. 7, D-24105 Kiel, GermanyCorrespondence: Axel Hauschild, MD. E-mail: [email protected]
Search for more papers by this authorS. Lischner
Department of Dermatology, University of Kiel, Schittenhelmstr. 7, D-24105 Kiel, GermanyCorrespondence: Axel Hauschild, MD. E-mail: [email protected]
Search for more papers by this authorE. Christophers
Department of Dermatology, University of Kiel, Schittenhelmstr. 7, D-24105 Kiel, GermanyCorrespondence: Axel Hauschild, MD. E-mail: [email protected]
Search for more papers by this authorA. Hauschild
Department of Dermatology, University of Kiel, Schittenhelmstr. 7, D-24105 Kiel, GermanyCorrespondence: Axel Hauschild, MD. E-mail: [email protected]
Search for more papers by this authorM. Möller
Department of Dermatology, University of Kiel, Schittenhelmstr. 7, D-24105 Kiel, GermanyCorrespondence: Axel Hauschild, MD. E-mail: [email protected]
Search for more papers by this authorS. Lischner
Department of Dermatology, University of Kiel, Schittenhelmstr. 7, D-24105 Kiel, GermanyCorrespondence: Axel Hauschild, MD. E-mail: [email protected]
Search for more papers by this authorE. Christophers
Department of Dermatology, University of Kiel, Schittenhelmstr. 7, D-24105 Kiel, GermanyCorrespondence: Axel Hauschild, MD. E-mail: [email protected]
Search for more papers by this author
References
- 1 World Health Organisation. WHO Handbook for reporting results of cancer treatment . WHO, Geneva, 1979.
- 2 Grob JJ, Dreno B & De La Salmoniere P et al. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma. Lancet 1998; 351: 1905 – 10.DOI: 10.1016/s0140-6736(97)12445-x
- 3 Pehamberger H, Soyer HP & Steiner A et al. Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group. J Clin Oncol 1998; 16: 1425 – 9.
- 4 Kirkwood JM, Strawderman MH & Ernstoff MS et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996; 14: 7 – 17.
- 5 Falkson CI, Ibrahim J & Kirkwood JM et al. Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol 1998; 16: 1743 – 51.
- 6 David WS. Myoglobinuria. Neurol Clin 2000; 18: 215 – 43.
- 7 Greenfield SM, Harvey RS & Thompson RPH. Rhabdomyolysis after treatment with interferon alfa. Br Med J 1994; 309: 512.
- 8
Anderlini P,
Buzaid AC &
Legha SS.
Acute rhabdomyolysis after concurrent adminstration of interleukin-2, interferon-alfa, and chemotherapy for metastatic melanoma.
Cancer
1995; 76: 678
–
9.
10.1002/1097-0142(19950815)76:4<678::AID-CNCR2820760422>3.0.CO;2-Q CAS PubMed Web of Science® Google Scholar
- 9 Reinhold U, Hartl C & Hering R et al. Fatal rhabdomyolysis and multiple organ failure associated with adjuvant high-dose interferon alfa in malignant melanoma. Lancet 1997; 349: 540 – 1.
